A 35-year-old man with focal seizures refractory to monotherapy is being evaluated for polytherapy. Before adding a second antiepileptic, the neurologist wants to assess baseline hepatic and renal function and establish a baseline for future monitoring. Which investigation is most appropriate to guide drug selection and dosing in this patient?

Explanation

## Pre-Polytherapy Assessment in Refractory Epilepsy ### Clinical Context When initiating polytherapy with antiepileptics, baseline assessment of organ function is critical because: - Most antiepileptics are hepatically metabolized (phenytoin, carbamazepine, valproate, phenobarbital) - Renal excretion is important for some drugs (levetiracetam, gabapentin) - Drug interactions and toxicity risk increase with polytherapy - Baseline labs allow safe dose titration and future monitoring ### Investigation of Choice **Key Point:** Liver function tests (LFTs), renal function tests (RFTs), and complete blood count (CBC) form the gold-standard baseline panel because: 1. **Hepatic assessment:** - Aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase - Guides dose selection for hepatically metabolized drugs - Establishes baseline to detect drug-induced hepatotoxicity (especially valproate) 2. **Renal assessment:** - Serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR) - Critical for drugs eliminated renally (levetiracetam, gabapentin, pregabalin) - Allows safe dosing adjustments in renal impairment 3. **Hematologic baseline:** - Hemoglobin, white blood cell count, platelet count - Detects pre-existing cytopenias - Establishes baseline to monitor for drug-induced hematologic toxicity (phenytoin, carbamazepine, valproate) ### Why This Panel Guides Drug Selection **High-Yield:** The baseline CBC + LFTs + RFTs determine which antiepileptic is safest to add: | Clinical Scenario | Preferred Drug | Avoided Drug | |---|---|---| | **Hepatic impairment** | Levetiracetam, gabapentin (renal excretion) | Phenytoin, valproate, carbamazepine | | **Renal impairment** | Phenytoin, carbamazepine, valproate (hepatic) | Levetiracetam, gabapentin (renal) | | **Baseline thrombocytopenia** | Levetiracetam, gabapentin | Valproate, carbamazepine (increase bleeding risk) | | **Baseline anemia** | Levetiracetam, gabapentin | Phenytoin, carbamazepine (worsen anemia) | ### Differential Approach to Other Investigations **Serum albumin and prothrombin time:** - Albumin reflects synthetic liver function; PT reflects coagulation status - Useful in advanced liver disease but not routine baseline assessment - Not necessary unless LFTs suggest significant hepatic dysfunction **EEG and brain MRI:** - Diagnostic tools for seizure localization and structural lesions - Do NOT guide drug selection or dosing - Already performed before polytherapy initiation **Therapeutic drug monitoring of current antiepileptic:** - Useful to optimize current monotherapy before adding a second drug - Does NOT assess organ function or guide selection of the new drug - Timing: obtain TDM after steady state (5–7 half-lives), not before polytherapy **Clinical Pearl:** In India, baseline CBC + LFTs + RFTs are standard of care before initiating any antiepileptic polytherapy. This practice prevents drug-drug interactions and organ-specific toxicity, especially with valproate (hepatotoxicity) and carbamazepine (hematotoxicity). **Mnemonic:** **LIVER** — Labs In Vitro to Evaluate Renal and hepatic function before antiepileptic polytherapy.